AtriCure (ATRC) Competitors $37.66 +1.93 (+5.40%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$37.67 +0.01 (+0.03%) As of 08/22/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATRC vs. TFX, ITGR, ATEC, IART, OFIX, SRDX, ANGO, ARAY, RMTI, and RSLSShould you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Teleflex (TFX), Integer (ITGR), Alphatec (ATEC), Integra LifeSciences (IART), Orthofix Medical (OFIX), Surmodics (SRDX), AngioDynamics (ANGO), Accuray (ARAY), Rockwell Medical (RMTI), and ReShape Lifesciences (RSLS). These companies are all part of the "health care equipment" industry. AtriCure vs. Its Competitors Teleflex Integer Alphatec Integra LifeSciences Orthofix Medical Surmodics AngioDynamics Accuray Rockwell Medical ReShape Lifesciences Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings. Which has stronger valuation and earnings, TFX or ATRC? Teleflex has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeleflex$3.04B1.88$69.68M$4.2530.42AtriCure$465.31M4.02-$44.70M-$0.77-48.91 Which has more risk & volatility, TFX or ATRC? Teleflex has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, AtriCure has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500. Do institutionals & insiders have more ownership in TFX or ATRC? 95.6% of Teleflex shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 1.4% of Teleflex shares are held by company insiders. Comparatively, 3.5% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate TFX or ATRC? Teleflex presently has a consensus target price of $141.57, suggesting a potential upside of 9.49%. AtriCure has a consensus target price of $50.89, suggesting a potential upside of 35.13%. Given AtriCure's stronger consensus rating and higher possible upside, analysts clearly believe AtriCure is more favorable than Teleflex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teleflex 1 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00AtriCure 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer TFX or ATRC? In the previous week, Teleflex had 10 more articles in the media than AtriCure. MarketBeat recorded 21 mentions for Teleflex and 11 mentions for AtriCure. Teleflex's average media sentiment score of 1.28 beat AtriCure's score of 1.18 indicating that Teleflex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 15 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TFX or ATRC more profitable? Teleflex has a net margin of 6.31% compared to AtriCure's net margin of -7.27%. Teleflex's return on equity of 15.08% beat AtriCure's return on equity.Company Net Margins Return on Equity Return on Assets Teleflex6.31% 15.08% 8.85% AtriCure -7.27%-4.20%-3.19% SummaryTeleflex beats AtriCure on 9 of the 16 factors compared between the two stocks. Get AtriCure News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRC vs. The Competition Export to ExcelMetricAtriCureMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78B$10.77B$5.75B$9.62BDividend YieldN/A1.87%4.40%4.10%P/E Ratio-48.9121.2531.3026.05Price / Sales4.0229.38432.98193.75Price / CashN/A24.5537.7358.48Price / Book4.033.519.536.61Net Income-$44.70M$211.77M$3.26B$265.65M7 Day Performance6.23%4.44%2.13%2.02%1 Month Performance22.19%8.85%2.80%-0.31%1 Year Performance48.03%-9.03%30.68%19.06% AtriCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRCAtriCure3.1576 of 5 stars$37.66+5.4%$50.89+35.1%+54.7%$1.78B$465.31M-48.911,300News CoveragePositive NewsInsider TradeShort Interest ↑TFXTeleflex4.504 of 5 stars$120.24-0.4%$141.57+17.7%-45.9%$5.33B$3.05B28.2914,100Positive NewsITGRInteger4.0775 of 5 stars$105.61-1.1%$140.25+32.8%-10.5%$3.74B$1.79B46.5211,000Positive NewsATECAlphatec3.8884 of 5 stars$15.86+1.0%$18.50+16.6%+183.7%$2.32B$611.56M-14.04700Insider TradeIARTIntegra LifeSciences3.9969 of 5 stars$14.05-1.0%$18.63+32.6%-27.0%$1.11B$1.61B-2.154,396News CoverageOFIXOrthofix Medical2.8094 of 5 stars$14.51+2.0%$21.50+48.2%-12.7%$562M$799.49M-4.581,616SRDXSurmodics3.9822 of 5 stars$36.89-1.5%$43.00+16.6%-6.9%$535.59M$126.08M-29.99450News CoverageANGOAngioDynamics3.7206 of 5 stars$8.78+0.1%$19.00+116.4%+25.8%$356.36M$292.50M-10.58760ARAYAccuray4.7722 of 5 stars$1.62+15.7%$5.00+208.6%-30.0%$157.70M$458.51M-81.001,040High Trading VolumeRMTIRockwell Medical4.3862 of 5 stars$1.05+2.9%$4.00+281.0%-61.5%$35.12M$101.49M-17.50300Short Interest ↓Analyst RevisionRSLSReShape Lifesciences0.0177 of 5 stars$3.16-1.4%N/A-99.7%$8.49M$8.01M-0.0350Stock SplitGap DownHigh Trading Volume Related Companies and Tools Related Companies TFX Competitors ITGR Competitors ATEC Competitors IART Competitors OFIX Competitors SRDX Competitors ANGO Competitors ARAY Competitors RMTI Competitors RSLS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRC) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.